title: Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.
abstract: This study examines the relationship between fibrillar beta-amyloid (Aβ) deposition and reduced glucose metabolism, a proxy for neuronal dysfunction, in cognitively normal (NL) individuals with a parent affected by late-onset Alzheimer's disease (AD). Forty-seven 40-80-year-old NL received positron emission tomography (PET) with (11)C-Pittsburgh compound B (PiB) and 18F-fluoro-2-deoxy-d-glucose (FDG). These included 19 NL with a maternal history (MH), 12 NL with a paternal history (PH), and 16 NL with negative family history of AD (NH). Automated regions of interest, statistical parametric mapping, voxel-wise intermodality correlations, and logistic regressions were used to examine cerebral-to-cerebellar PiB and FDG standardized uptake value ratios across groups. The MH group showed higher PiB retention and lower metabolism in AD regions compared with NH and PH, which were negatively correlated in posterior cingulate, frontal, and parieto-temporal regions (Pearson r ≤ -0.57, p ≤ 0.05). No correlations were observed in NH and PH. The combination of Aβ deposition and metabolism yielded accuracy ≥ 69% for MH vs. NH and ≥ 71% for MH vs. PH, with relative risk = 1.9-5.1 (p values < 0.005). NL individuals with AD-affected mothers show co-occurring Aβ increases and hypometabolism in AD-vulnerable regions, suggesting an increased risk for AD.
authors.affiliation: Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA. lisa.mosconi@nyumc.org
authors.forename: Lisa
authors.initials: L
authors.lastname: Mosconi
authors.forename: Juha O
authors.initials: JO
authors.lastname: Rinne
authors.forename: Wai H
authors.initials: WH
authors.lastname: Tsui
authors.forename: John
authors.initials: J
authors.lastname: Murray
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Lidia
authors.initials: L
authors.lastname: Glodzik
authors.forename: Pauline
authors.initials: P
authors.lastname: McHugh
authors.forename: Schantel
authors.initials: S
authors.lastname: Williams
authors.forename: Megan
authors.initials: M
authors.lastname: Cummings
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Pirraglia
authors.forename: Stanley J
authors.initials: SJ
authors.lastname: Goldsmith
authors.forename: Shankar
authors.initials: S
authors.lastname: Vallabhajosula
authors.forename: Noora
authors.initials: N
authors.lastname: Scheinin
authors.forename: Tapio
authors.initials: T
authors.lastname: Viljanen
authors.forename: Kjell
authors.initials: K
authors.lastname: Någren
authors.forename: Mony J
authors.initials: MJ
authors.lastname: de Leon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications*; D000682:Amyloid / Q000378:metabolism*; D000814:Aniline Compounds; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D001931:Brain Mapping; D003072:Cognition Disorders / Q000000981:diagnostic imaging / Q000209:etiology / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D011569:Psychiatric Status Rating Scales; D012680:Sensitivity and Specificity; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000682:Amyloid; D000814:Aniline Compounds; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18